|
Video: What is a Stock Split?
|
|
Design Therapeutics is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTAC molecules. The U.S. Food and Drug Administration has granted Fast Track designation to Co.'s primary Friedreich ataxia (FA) GeneTAC development candidate (DT-216) for the treatment of patients with FA. Co.'s second GeneTAC development candidate (DT-168) is an eye drop for the treatment of Fuchs Endothelial Corneal Dystrophy. Co.'s third program based on the GeneTAC platform is myotonic dystrophy type-1. Co. continues to develop its GeneTAC portfolio in preclinical studies to address other serious nucleotide repeat expansion-driven monogenic diseases. According to our DSGN split history records, Design Therapeutics has had 0 splits. | |
|
Design Therapeutics (DSGN) has 0 splits in our DSGN split history database.
Looking at the DSGN split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Design Therapeutics shares, starting with a $10,000 purchase of DSGN, presented on a split-history-adjusted basis factoring in the complete DSGN split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/30/2021 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$29.52 |
|
End price/share: |
$3.91 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-86.75% |
|
Average Annual Total Return: |
-49.09% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,324.39 |
|
Years: |
2.99 |
|
|
|
|
|